Abstract
Objective To assess whether utilization of health care services for newly vaccinated health care workers changed after media attention about fatal side effects of the AstraZeneca vaccine on March 11th, 2021, and whether changes differed by age, sex, or occupation.
Data sources We utilized individual-level data on health care use, vaccination, employment, and demographics available in the Norwegian emergency preparedness register BeredtC19.
Study design Using an event-study design with a matched comparison group and multiple time periods, we compared the change in primary and inpatient specialist care use for vaccinated health care workers from 14 days before to 14 days after the information shock on March 11th, 2021.
Data collection Not applicable.
Principal findings Primary health care use rose sharply by 66% (95%CI 60.7 to 71.3) the week following March 11th for those vaccinated with AstraZeneca (n = 87,632), compared with no rise for the unvaccinated comparison group (n = 175,264). Utilization of inpatient care also rose by 20% (95%CI -3.7 to 43.7) in week one and 61% (95%CI 27.1 to 94.9) in week two after March 11th. The sharpest increase in primary health care use was found for women aged 18-44 (83%, 95%CI 76.6 to 89.5) and for cleaners working in the health care sector (103 %, 95%CI 36.1 to 166.9).
Conclusions Health care use was highly affected by the media reports of a few fatal or severe side effects of the AstraZeneca vaccine. Our results suggest that the reports did not only lead vaccinated individuals to contact primary health care more, but also that physicians referred and treated more cases to specialist care because of the new information.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the Norwegian Institute of Public Health. No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The establishment of an emergency preparedness register forms part of the legally mandated responsibilities of The Norwegian Institute of Public Health (NIPH) during epidemics. Institutional board review was conducted, and the Ethics Committee of South-East Norway confirmed (June 4th, 2020, #153204) that external ethical board review was not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The individual-level data used in this study is not publicly available due to privacy laws.
